PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting AKT is therefore a highly attractive anti-cancer strategy with multiple AKT inhibitors now in various stages of clinical development. In this review, we summarise the role and regulation of AKT signalling in normal cellular physiology. We highlight the mechanisms by which AKT signalling can be hyperactivated in cancers and discuss the past, present and future clinical strategies for AKT inhibition in oncology.
Introduction
The AGC kinases, named after the protein A, G and C kinases, are an evolutionarily conserved group of proteins that share a hydrophobic motif at the c-terminus of their catalytic core. This motif, composed of F-X-X-F/Y-S/T-Y/F, is known as the PIF-pocket and regulates catalytic activity (Arencibia, Pastor-Flores, Bauer, Schulze, & Biondi, 2013; Manning & Cantley, 2007) . The AGC kinase family comprises 14 family members, of which AKT (also known as PKB; protein kinase B) is a key member.
There are three AKT isoforms, transcribed from separate genes, which share three highly conserved domains: a central catalytic domain and two regulatory domains: a lipid-binding N-terminal PH (plektrin homology) domain, and the hydrophobic motif (Fig. 1) . The PH domain contains a lipid-binding module that promotes the interaction of AKT with the plasma membrane, an important step in AKT activation. The hydrophobic motif contains an important docking site for the activating kinase PDK1 (3-phosphoinositide-dependent kinase-1) and also provides allosteric regulation of catalytic activity (Scheid & Woodgett, 2003 ; Fig. 1 ). There is approximately 80% sequence homology between the isoforms with most variability occurring in the linker region between the PH and catalytic domains (Brodbeck, Cron, & Hemmings, 1999; Cheng et al., 1992; Hanada, Feng, & Hemmings, 2004; Jones, Jakubowicz, Pitossi, Maurer, & Hemmings, 1991) .
AKT activation
Mechanisms of AKT activation have been reviewed previously (Liao & Hung, 2010; Scheid & Woodgett, 2003) , but essentially, AKT activity is regulated downstream of receptor tyrosine kinases (RTKs), such as those within the EGF (epidermal growth factor), insulin, PDGF (platelet derived growth factor), FGF (fibroblast growth factor) and VEGF (vascular endothelial growth factor) families. RTKs activate class I phosphatidylinositol 3-kinases (PI3K), either directly, or in conjunction with adaptor proteins such as IRS-1/2 (insulin receptor substrate-1/2; Fig. 2 ). The PI3Ks phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). AKT binding to PIP3 at the plasma membrane induces a conformational change that results in phosphorylation of AKT, predominantly on two highly conserved residues, Thr 308 and Ser 473 leading to AKT activation ( Fig. 1) . Phosphorylation of Thr 308 in the activation T-loop of the catalytic domain by PDK1, results in a conformational change that enhances substrate affinity and promotes AKT kinase activity (Alessi et al., 1997) . Phosphorylation of Ser 473 within the PIF pocket of AKT by mTORC2 (mammalian target of rapamycin complex 2) is thought to promote AKT activity by increasing the affinity of AKT to PDK1 (Sarbassov, Guertin, Ali, & Sabatini, 2005) . In fact, multiple different kinases for Ser 473 have been described in the literature and it's likely that mechanisms determining full activation of AKT are context dependent. It has been accepted, for example, that following DNA damage, the PI3K-like kinase (PIKK) DNA-PK (DNA-dependent protein kinase) is responsible for AKT Ser 473 phosphorylation and that AKT activation prevents apoptosis following ionizing radiation (Bozulic, Surucu, Hynx, & Hemmings, 2008) . Multiple other phosphorylation sites on AKT have been described, although the physiological importance of these is not yet fully understood (Risso, Blaustein, Pozzi, Mammi, & Srebrow, 2015) and mechanisms of constitutative activation of AKT signalling in cancer are discussed further below. Important negative regulators of the PI3K/AKT signalling pathway include the tumour suppressor genes and phosphatases PTEN (phosphatase and tensin homolog), PP2A (protein phosphatase 2A) and PHLPP (PH domain and leucine rich repeat protein phosphatase 1; Gao, Furnari, & Newton, 2005) , which dephosphorylate PIP3, AKT pThr 308 and AKT pSer 473 respectively (Toker & Marmiroli, 2014; Fig. 2) . PTEN hydrolyses the 3′-phosphate on PIP3 to terminate PI3K signalling. The SH2 domain-containing inositol phosphatases (SHIP-1/2) are able to hydrolyse the 5′-phosphate on PIP3 to generate PI(3,4)P2, the function of which is not clear, although some studies suggest that like PIP3, PI(3,4)P2 is able to facilitate PDK1 activation of AKT (Gewinner et al., 2009) . Recently, a fourth putative tumour suppressor of the PI3K/AKT pathway has been described namely, polyphosphate 4-phosphatase type II (INPP4B; Gewinner et al., 2009) . This is able to dephosphorylate PI(3,4)P2 to PI(3)P in vitro, resulting in attenuation of AKT signalling (Gewinner et al., 2009) . Of all the tumour suppressors, PHLPP in particular is a key regulator of AKT activity and its ability to fine-tune the PI3K/AKT pathway is discussed in greater detail below.
Downstream signalling of AKT
A consensus phosphorylation motif has been described for AKT substrates: R-X-R-X-X-S/T-B where X represents any amino acid and B represents bulky hydrophobic residues (Alessi, Caudwell, Andjelkovic, Hemmings, & Cohen, 1996) . Numerous AKT substrates have been published in the literature, with several being extensively validated that impact on multiple cellular processes including: cell growth, proliferation and survival, cellular metabolism, glucose uptake and angiogenesis (Table 1; Manning & Cantley, 2007) . Importantly there is great overlap and crosstalk between substrate functions, with many substrates being regulated directly by AKT phosphorylation, as well as indirectly, through AKT-mediated phosphorylation of transcription factors. AKT signalling therefore plays a central role in multiple pathways involved in tumourigenesis and hyperactivation of the PI3K/AKT pathway is a common occurrence in cancer (Liu, Cheng, Roberts, & Zhao, 2009 ).
AKT in normal physiology
As well as playing a central role in cancer, AKT signalling is also essential for normal cellular physiology. In adults, AKT1 expression is ubiquitous, expression of AKT2 is elevated in insulin-responsive tissues and expression of AKT3, whilst found at low levels in all tissues, is more highly expressed in the brain and endocrine tissues (http://www. proteinatlas.org/; Uhlen et al., 2010 Uhlen et al., , 2015 .
AKT plays an essential role in glucose homeostasis and a deleterious effect of pharmacological inhibition of AKT is hyperglycaemia and hyperinsulinaemia which correlates with peak plasma level drug concentrations (Crouthamel et al., 2009 ). The AKT substrate GSK3β (glycogen synthase kinase beta) phosphorylates and inhibits glycogen synthase, preventing glycogen synthesis. AKT activation results in phosphorylation and inhibition of GSK3β relieving the inhibitory effect on glycogen synthase, resulting in glycogen synthesis. As well as stimulating glycogen synthesis, AKT also promotes cellular uptake of glucose by prompting translocation of the glucose transporter GLUT4 to the plasma membrane. The AKT substrate directly involved in this process has not been well-defined and several candidate proteins are described in the literature (Manning & Cantley, 2007) .
AKT function (especially AKT1 and AKT2) is also important for regulating cardiac growth, contractile function and coronary angiogenesis. It is essential for maintaining normal endothelial function and endothelial nitric oxide synthesis, with increased atherosclerosis and peripheral vascular disease demonstrated in Akt1 knockout mice (Hers, Vincent, & Tavare, 2011) . AKT also has a pro-thrombotic effect, promoting platelet activation and aggregation, highlighting the need for tight control of AKT signalling (Hers et al., 2011) . As well as its role in the cardiovascular and endocrine systems, AKT has also been shown to be neuro-protective and plays a role in synaptic transmission between neurons (Hers et al., 2011) . Taken together therefore, given the wide-ranging effects of AKT signalling in normal human physiology, there is vast scope for significant on-target as well as off-target effects of AKT inhibitors in the clinic.
Selectivity within the AKT pathway
The phenotypes of Akt null mice have suggested non-redundant roles for the three isoforms, with Akt1 knockout being embryonic lethal, Akt2 null mice developing insulin-resistant diabetes and Akt3 knock-out resulting in microcephaly (Toker & Marmiroli, 2014) . In keeping with this, findings from pre-clinical studies, are consistent with AKT isoforms having partially overlapping, but distinct functions in cancer cells (Clark & Toker, 2014; Toker & Marmiroli, 2014) . Phosphoproteomic screens have demonstrated unique and common substrates for each of the AKT isoforms and functional studies have started to highlight the physiological relevance of these findings, for example during RNA processing in lung cancer (Sanidas et al., 2014) . Isoform-mediated specificity has been best studied in breast cancer models however, where differential functions of AKT1, -2 and -3 in both inhibiting and promoting cell migration and proliferation have been demonstrated (Clark & Toker, 2014) .
AKT1 has been shown to be important for G1-S checkpoint transition and proliferation, whereas AKT2 regulates cell-cycle exit through its interaction with p21 (Héron-Milhavet et al., 2006) . In a recent study in triple negative breast cancer, AKT3, rather than AKT1 activity was most important for cellular proliferation (Chin, Yoshida, et al., 2014) , suggesting a degree of context specificity for these findings. Interestingly, it has been observed that although activating mutations in AKT1 result in accelerated tumourigenesis, metastatic dissemination is decreased due to inhibitory effects of AKT1 on tumour cell invasion and migration (Chin & Toker, 2010; Hutchinson, Jin, Cardiff, Woodgett, & Muller, 2004) . By contrast, AKT2 activity promotes tumour invasion and metastatic dissemination in mouse breast cancer models (Dillon et al., 2009; Maroulakou, Oemler, Naber, & Tsichlis, 2007) . In addition, it has recently been shown that INPP4B inhibition of AKT2 is important for metastatic spread of follicular thyroid cancer (Chew et al., 2015) . A number of different AKT1/2 substrates have been described that may account for the differential phenotype of cellular migration, which play a role in epithelial-mesenchymal transition (EMT), including the NFAT transcription factor (Yoeli-Lerner et al., 2005) , palladin (Chin & Toker, 2010) , the integrin β subunit (Arboleda et al., 2003) and the miR-200 family of micro-RNAs (Iliopoulos et al., 2009 ). There are likely to be many more (Clark & Toker, 2014) and the relative importance of each Table 1 The effect of AKT phosphorylation on well-described substrates (Manning & Cantley, 2007) . BAD (BCL2 associated agonist of cell death); FOXO (Forkhead Box); MDM2 (MDM2 oncogene); TSC2 (tuberous sclerosis 2); PRAS40 (proline rich Akt substrate); CDKN (cyclin-dependent kinase inhibitor); GSK3β (glycogen synthase kinase beta).
Cellular function
Substrate Effect of AKT phosphorylation
Cell survival BAD Release of pro-survival Bcl-2 proteins from BAD. FOXO1 FOXO3a FOXO4 14-3-3 mediated export of FOXO transcription factors from the nucleus, blocking transcription of pro-apoptotic proteins such as BIM and FasL.
MDM2
Nuclear translocation of MDM2 resulting in P53 ubiquitin-mediated degradation. Cell growth TSC2 Inhibits TSC2 function, resulting in mTORC1 activation.
PRAS40
Phosphorylation of PRAS40 by AKT results in 14-3-3 mediated sequestration of PRAS40 and mTORC1 activation. Cell proliferation CDKN1B/p27 CDKN1A/p21
Prevents nuclear localisation of cyclin dependent kinases, blocking cell-cycle inhibitory effects and resulting in loss of the G1-S checkpoint. Glucose homeostasis Unknown Results in translocation of glucose transporter 4 (GLUT4) to the plasma membrane.
GSK3β
Inhibits glycogen synthase 3 (GSK3), thereby inhibiting glycogen synthesis. Angiogenesis eNOS Activates endothelial nitric oxide synthase (eNOS), resulting in vasodilatation, vascular remodelling and angiogenesis.
of these is likely to depend on tumour subtype, as well as perhaps tumour stage and genetic background. An example of this is that PTEN deficient tumour cells have recently been shown to be dependent, specifically on AKT2 for survival (Chin, Yuan, Balk and Toker, 2014) . This was shown to be true for prostate cancer, breast cancer and glioblastoma PTEN deficient cells lines and was at least in part, mediated through AKT2 dependent upregulation p21 (Chin, Yuan, et al., 2014) . Several lines of evidence suggest that AKT does not need to be fully activated in order to phosphorylate all substrates. This suggests that different AKT substrates and therefore different cellular functions of AKT depend on varying levels of AKT activation. For example AKT Ser 473 phosphorylation appears to be dispensable for phosphorylation of the AKT targets TSC2 and GSK3, as well as the TORC1 effectors, S6K and 4E-BP1, but not for FOXO1/3a (Jacinto et al., 2006) . Interestingly, in patient non-small cell lung cancer samples, AKT Thr 308 correlates with phosphorylation of AKT substrates PRAS40, TSC2 and TBC1D4, whereas AKT Ser 473 phosphorylation does not (Vincent et al., 2011) . This raises an important point clinically, when trying to determine whether or not a tumour might be dependent on AKT signalling for survival, suggesting the AKT Thr 308 is a more suitable biomarker of AKT activation than AKT Ser
473
. Relative levels of the negative regulators of the PI3K/AKT pathway will also ultimately affect amplitude of AKT activation. For example, the PHLPP isoforms -1 and -2 have been shown to preferentially hydrolyse Thr 308 on AKT2 and AKT3 respectively (Brognard, Sierecki, Gao, & Newton, 2007) . Cellular location and post-translational modification of AKT isoforms also contribute to specificity within the pathway (Clark & Toker, 2014) and untangling all of these factors within the context of cancer is proving to be a considerable challenge.
Feedback loops within the PI3K/AKT signalling pathway
The PI3K/AKT signalling pathway is far from linear with multiple negative feedback loops fine-tuning overall activation levels (Carracedo & Pandolfi, 2008) . The activity of the S6 kinases (S6K1/2), which are phosphorylation targets of mTORC1 plays a pivotal role in negatively regulating AKT activity. IRS-1 (insulin receptor substrate-1) is an adaptor protein required for binding of the class IA PI3Ks with insulin and insulin growth factor (IGF) receptors. Phosphorylation of IRS-1 by S6K1 inhibits its interaction with insulin and IGF receptors and also promotes proteasomal degradation of IRS-1 (Harrington, Findlay, & Lamb, 2005) , thereby dampening PI3K signalling and reducing AKT activity. In addition to its effects on AKT activity via upstream inhibition of PI3K signalling, the mTORC1 complex also inhibits AKT by upregulating PHLPP1 translation (Liu, Stevens, & Gao, 2011) , the phosphatase responsible for dephosphorylating AKT pSer 473 (Fig. 3 ).
AKT activity is also self-limiting through its substrate GSK3β; the kinase activity of which is negatively regulated by AKT phosphorylation ( Fig. 3 ; Li, Liu, & Gao, 2009 ). GSK3β activation results in phosphorylation and subsequent ubiquitin mediated degradation of PHLPP (Li et al., 2009) . AKT activation therefore results in GSK3β inactivation and high levels of PHLPP, which in turn, puts the brakes on the AKT signalling pathway.
Opposing the above mechanisms that limit the activity of the PI3K/ AKT pathway, AKT inhibition results in up-regulation of RTKs, in part through loss of mTORC1 signalling, but also due to FOXO-dependent transcriptional increases in RTK expression . This up-regulation of upstream pathway components in part will compensate for pharmacological inhibition of more downstream players and has been shown to contribute to resistance to AKT inhibitors (Garrett, Olivares, et al., 2011) .
In the context of normal growth factor signalling, it's easy to appreciate why it's advantageous that in 'times of plenty', chronic activation of mTORC1, leads to attenuation of AKT signalling (Manning, 2004) . As discussed below, multiple components of the PI3K pathway are mutated or deleted in cancer cells and the level of the aberration within the pathway will have profoundly different effects on AKT activity depending on whether or not the negative regulatory feedback loops are intact. Equally, chronic vs acute inhibition of the pathway may result in very different signalling patterns. This makes targeting the pathway a significant challenge in oncology and also has implications for dosing schedules of AKT inhibitors.
AKT activation in cancer
The PI3K/AKT pathway is the most commonly disrupted signalling pathway in human cancers (Millis, Ikeda, Reddy, Gatalica, & Kurzrock, 2016) . PI3K/AKT pathway aberrations have been identified in up to 40% of all tumour types, with PTEN loss by immunohistochemistry occurring most frequently (30%), followed by mutations in PIK3CA (13%), PTEN (6%) and AKT (1%; Millis et al., 2016) . Whilst activating AKT mutations is relatively uncommon, AKT activation can arise as a result of several other genomic aberrations.
AKT amplification
In keeping with its role in promoting EMT transition and promoting metastatic disease, AKT2 is frequently amplified in cancer. Analysis of the cBioPortal database for cancer genomics demonstrates that AKT2 amplification is found in up to 16% of pancreatic cancers, 16% of uterine cancers, 13% of breast cancers and 5-10% of ovarian, lung and bladder cancers (Fig. 4A) . Early work also demonstrated that siRNA depletion of AKT2 resulted in reduced cell growth and invasiveness only in cells overexpressing AKT2, consolidating its role in tumourigenesis (Cheng et al., 1996) . By contrast, AKT1 amplification is found less frequently across tumour types, occurring in 20% of neuroendocrine prostate cancers, 10% of pancreatic cancers and 3-5% of breast and serous ovarian cancers. To date, high levels of AKT3 amplification have been identified most often in breast cancers and as discussed, AKT3 may be the predominant isoform responsible for growth and proliferation of triple negative breast cancers (Chin, Yoshida, et al., 2014) . Interestingly, high levels of AKT3 expression have also been demonstrated in over 25% of neuroendocrine prostate cancers (Fig. 4A) .
AKT mutations
In contrast to amplifications, mutations in AKT2 are found much less frequently and to our knowledge, no commonly occurring functionally activating mutations in AKT2 have been described. AKT1 is the most frequently mutated isoform in tumours and this occurs at low frequency (approximately 1% of all cancers; Fig. 4B ; www.cbioportal.org; Cerami et al., 2012; Gao et al., 2013) . Several functionally transforming mutations of AKT1 have been described however (Yi, Axtmayer, Gustin, Rajpurohit, & Lauring, 2013) , the predominant mutation is AKT1 E17K (Carpten et al., 2007) . This glutamic acid to lysine substitution within the lipid-binding pocket of AKT1 results in pathological localisation of AKT1 E17K to the plasma membrane and subsequent constitutative activation of AKT1 signalling (Carpten et al., 2007) . In contrast to physiological AKT1 activation that occurs upon binding of AKT1 to PIP3 at the plasma membrane, the E17K mutation in AKT1 alters PIP specificity, resulting in high affinity binding to highly abundant PIP2 within the plasma membrane (Landgraf, Pilling, & Falke, 2008) . AKT1 E17K therefore utilises both PIP3 as well as PIP2 for its activation and as a result, remains constitutively active at the cell membrane (Landgraf et al., 2008) . Both allosteric and catalytic inhibitors of AKT are capable of suppressing AKT1 E17K activity and subsequently inhibiting growth of tumours harbouring AKT1 E17K in breast cancer models . AKT1 E17K mutations are found most frequently in breast, bladder, cervix and prostate cancers (Fig. 4B) . Inhibition of AKT1 E17K tumours in a clinical setting has also now been demonstrated and will be discussed in more detail below.
Alterations of other proteins of the PI3K/AKT signalling pathway
Over-expression or activating mutations of proteins upstream of AKT in the PI3K/AKT pathway result in AKT activation, as do loss of the tumour suppressor proteins: PTEN, PHLPP, PP2A and INPP4B (Liu et al., 2009). Germline mutations in PTEN result in PTEN hamartoma syndromes, of which Cowden's syndrome is the best described; characterised by the development of multiple hamartomas and with increased risk of carcinomas of the breast, thyroid, endometrium and kidney. Somatic PTEN loss is most commonly identified in endometrial carcinoma, prostate carcinoma and glioblastoma and can arise due to mutations, insertions and deletions throughout the PTEN gene (Hollander, Blumenthal, & Dennis, 2011) .
The clinical development of AKT inhibitors
Inhibiting PI3K/AKT signalling has long been an attractive therapeutic approach in oncology. Numerous compounds that inhibit the pathway at all levels are now in clinical development, including those targeting AKT (Yap et al., 2008) . AKT inhibitors fall predominantly into two separate classes. Allosteric inhibitors of the AKT PH-domain prevent localisation of AKT to the plasma membrane, thereby blocking AKT phosphorylation and activation. The second class of inhibitors comprise ATP-competitive inhibitors of AKT, of which there are several in the early stages of clinical development (Table 2 ).
Monotherapy with AKT inhibitors
The AKT inhibitors that have entered clinical evaluation have been discussed in alphabetical order.
AFURESERTIB (GSK2110183) and GSK2141795
Afuresertib (GSK2110183) and GSK2141795 (GlaxoSmithKline) are both orally bioavailable, ATP-competitive inhibitors of AKT1-3 which have anti-tumour effects in vitro and in vivo as monotherapy and in combination with the MEK inhibitor trametinib (GSK1120212; Dumble et al., 2014) . In a phase I trial of afuresertib in patients with haematological malignancies, DLTs consisted of deranged liver function tests and the MTD was established as 125 mg daily. The most frequent (N10% of patients) treatment-related adverse events (AEs) were nausea (23.3%), diarrhoea (20.5%), dyspepsia (19.2%), fatigue (16.4%), gastrointestinal reflux disease (15.1%), and anorexia (13.7%). Promising antitumour activity was demonstrated in patients with multiple myeloma (Spencer et al., 2014) . Preliminary data from a phase I study of GSK2141795 demonstrated an MTD of 75 mg daily with DLTs of G3 hyperglycaemia, G4 hypoglycaemia, G3 hypoglycaemia and G2 stomatitis with promising tumour responses seen in patients with an activated PI3K/AKT pathway (Burris et al., 2011) .
ARQ 092 and ARQ 751
ARQ 092 and ARQ 751 (ArQule) are both highly potent allosteric inhibitors of wild type and AKT
E17K
, with ARQ 751 having enhanced PK properties and potency (Table 2 ; Lapierre et al., 2016; Yu et al., 2015) . Structural studies have shown that allosteric inhibitors bind to a region between the PH-domain and kinase domain on AKT (Wu et al., 2010) . This stabilises the PH-domain in a 'closed' conformation which blocks ATP binding to the kinase site, obstructing the phospholipid binding site, and thereby inhibiting AKT recruitment to the plasma membrane (Wu et al., 2010) .
Preliminary data from a phase Ia dose escalation trial of ARQ 092 has demonstrated common drug-related adverse events (≥ 10%) of hyperglycaemia (30%), macular-papular rash (28%), nausea (20%), diarrhoea (19%), pruritis (16%), fatigue (15%_ and decreased appetite (14%; Tolcher et al., 2016) . Early evidence of anti-tumour activity has been shown with two durable partial responses in patients with activating PIK3CA mutations (Tolcher et al., 2016) and promising clinical activity in patients with AKT E17K mutations has also now been demonstrated in the phase Ib expansion cohort (Abbadessa et al., 2015) . Interestingly, AKT inhibition using ARQ 092 is also being explored for the treatment of Proteus syndrome (Lindhurst et al., 2015) . Rarely a somatic AKT1 E17K mutation can arise during development that results in Proteus syndrome; a progressive, mosaic, segmental overgrowth syndrome that can affect any part of the body (Biesecker, 2001) . The severity and extent of tissue involvement is unique to each patient, with bone, fat, skin and connective tissue being most commonly involved (Biesecker, 2001) . Affected patients have an increased risk of malignancy, including mesothelioma and breast cancer, and are at high risk of life-threatening venous thromboembolism (Biesecker, 2001 ). In preclinical studies, ARQ 092 has been shown to suppress AKT signalling in cell lines and tissues from patients with Proteus syndrome (Lindhurst et al., 2015) . In contrast to the treatment of AKT-mutated cancers, the aim of such treatments is to restore physiological levels of AKT signalling in cells rather cytotoxicity. A phase I trial of ARQ 092 is currently recruiting children and adults with Proteus syndrome (NCT02594215) and preliminary data suggest that doses of ARQ 092 that are significantly lower than the MTD for cancer will be sufficient to treat patients with Proteus syndrome (Lindhurst et al., 2015) .
AZD5363
AZD5363 (Astrazeneca) is a potent competitive kinase domain inhibitor of AKT1-3, which in pre-clinical studies has been shown to inhibit phosphorylation of AKT substrates (PRAS40, GSK3β and S6) and tumour growth in xenograft models (Davies et al., 2012) . The presence of an activating PIK3CA mutation, AKT1 E17K mutation or PTEN loss, in the absence of a significant KRAS (or other activating mutation in an alternative pro-survival pathway) significantly correlated with sensitivity to AZD5363 across a range of tumour cell lines (Davies et al., 2012 . Interestingly, continuous low doses of AZD5363 had a predominantly anti-proliferative effect on cells when given as monotherapy and significant levels of apoptosis were only observed using an intermittent high dose schedule, suggesting that intermittent high dose schedules might be a more effective clinical strategy for the treatment of AKT dependent tumours (Davies et al., 2012) . A phase I trial of AZD5363 monotherapy in patients with solid tumours has investigated the toxicity, pharmacokinetics (PK) and PD of intermittent vs continuous dosing . Three schedules were explored: continuous dosing (7/7), four days a week (4/7) and two days a week (2/7) of which the MTDs were 320 mg BID, 480 mg BID and 640 mg BID respectively. The DLTs were rash and diarrhoea for 7/7, and hyperglycaemia for 2/7 with no DLTs identified for 4/7. As expected following AKT inhibition, the most common causally related adverse events ≥ CTC Grade 3 were hyperglycaemia (20%), diarrhoea (10%), rash (10%), nausea (3%) and fatigue (1%). PK profiles at 480 mg BID (4/7) resulted in higher steady state levels of AZD5363 compared to continuous dosing at lower drug concentrations and were consistent with exposures that resulted in tumour regression in preclinical models. Pre-and post-treatment biopsies confirmed target engagement in tumour tissue, with an increase in pAKT and reductions in pGSK3β and pPRAS40. Based on PK, PD and toxicity data, 480 mg BID (4/7) was determined as the RP2D of AZD5363. Early data from an expansion cohort at this dose in patients with breast or gynaecological tumours harbouring PIK3CA mutations demonstrated anti-tumour activity in approximately 50% of patients with PIK3CA mutations although the magnitude of response in most patients was not deemed sufficient to go forward with monotherapy in a PIK3CA mutant population. Preliminary expansion data at the RP2D in patients with AKT1
E17K mutations (without concomitant RAS/RAF mutations) has shown very promising antitumour activity. At the time of reporting, 13/17 (76%) ER+ ve breast, 8/10 (80%) gynaecological and 10/12 (83%) other solid tumour patients demonstrated target lesion responses with 4 (24%), 2 (20%) and 3 (25%) partial responses (PRs) respectively (Hyman et al., 2015) . A phase I trial of AZD5363 monotherapy in Japanese patients with solid tumours has also determined 480 mg BID (4/7) to be the RP2D and demonstrated 2 PRs in patients with AKT1 E17K mutations (Tamura et al., 2016) .
AKT1
E17K is therefore a promising predictive biomarker for response to AZD5363 monotherapy across a range of tumour types and the full results of this trial are awaited with interest. (Azaro et al., 2015; Garrett et al., 2011a) . 
Ipatasertib (GDC-0068)
Optimisation of ATP-competitive AKT inhibitors using structure based design led to the discovery of ipatasertib (GDC-0068; Genentech), a potent and highly selective inhibitor of AKT1-3 that causes dosedependent AKT signalling inhibition in cancer cells and xenograft tumour models (Blake et al., 2012; Lin et al., 2013) . In pre-clinical models, markers of hyperactive AKT signalling correlated with sensitivity to ipatasertib, including high basal phospho-AKT levels, PTEN loss and PIK3CA mutations (Lin et al., 2013) . Preliminary data from a phase I study established the MTD as 600 mg QD of ipatasertib, with two DLTs of fatigue at higher dose levels and a low incidence of clinically significant hyperglycaemia . A dose-and time-dependent PD response was demonstrated through inhibition of pGSKβ in platelet rich plasma in doses above 200 mg (Yan et al., , 2013 . As with AZD5363, the clinical focus for ipatasertib is now on combination studies (see below and Table 2 , Isakoff et al., 2014; Bendell et al., 2014; De Bono et al., 2016) .
MK-2206
MK-2206 (Merck; MSD) is the most clinically advanced allosteric inhibitor of AKT, although other allosteric inhibitors of AKT include ARQ092 (ArQule; Lapierre et al., 2016) , ARQ751 (ArQule; Yu et al., 2015) and BAY1125976 (Bayer; Politz et al., 2016;  Table 2 ).
MK-2206 is a predominantly AKT1/2 inhibitor with reduced potency against AKT3 (Yan, 2009) and has been shown to have single agent activity against a range of cell lines harbouring RTK activation, PTEN loss/mutation and/or AKT2 amplification (Lu et al., 2009) . A phase I trial of MK-2206 monotherapy in patients with solid tumours demonstrated a MTD of 60 mg on alternate days with DLTs of skin rash and stomatitis (Yap et al., 2011) . Drug related AEs included rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycaemia (21.2%), and diarrhoea (21.2%). MK-2206 had a long half life of 40-100 h and plasma concentrations declined in a biphasic manner (Yap et al., 2011) . On-target PD tumour effects were also demonstrated (decrease in AKT pSer 473 ).
Similarly to other AKT inhibitors, intermittent dosing schedules seem to be better tolerated and equally, if not more effective. Compared to the alternate day schedule, once weekly dosing of MK-2206 was equally as well tolerated up to a recommended phase II dose (RP2D) of 200 mg with pulsatile inhibition of AKT demonstrated in tumour biopsies (Yap et al., 2014) . Given the limited anti-tumour activity seen with MK-2206 monotherapy in phase II trials across a range of tumour types (Ahn et al., 2015; Dasari et al., 2016; Konstantinopoulos et al., 2014; Ramanathan et al., 2015; Ma et al., 2015; Konopleva, 2014; Oki et al., 2015; Doi et al., 2015; Fouladi et al 2014 , Ho et al., 2015 , attention has focused on combination trials (Table 2 and see below, Gonzalez-Angulo et al., 2015; Chien et al., 2016; Molife et al., 2014; Wisinski et al., 2016; Hudis et al., 2013; Tripathy et al., 2015; Tolcher et al., 2015a; Do et al., 2015; Chung et al., 2015; Lin et al., 2014; Lara et al., 2015; Brana et al., 2014; Gupta et al., 2015; Ma et al., 2016) .
Perifosine
The first AKT inhibitor to enter clinical development was in fact an alkylphospholipid, perifosine (D-21266; KRX0401; Aeterna Zentaris). Alkylphospholipids accumulate in the plasma membrane and inhibit AKT activation by disrupting the interaction between AKT and the phospholipids (Kondapaka, Singh, Dasmahapatra, Sausville, & Roy, 2003) . As such, these compounds are relatively non-selective (Hideshima et al., 2006) . In clinical studies, doses of oral perifosine are limited by gastro-intestinal (GI) toxicity when administered daily and several studies have tested different loading and maintenance schedules in order to achieve administration of biologically active doses without intolerable toxicity (Crul et al., 2002; Figg et al., 2014; Unger et al., 2010; Van Ummersen et al., 2004) . Multiple Phase II trials have been conducted using a loading dose/maintenance dose schedule (Table 2 , Leighl et al., 2008; Argiris et al., 2006; Ernst et al., 2005; Marsh et al., 2007; Posadas et al., 2005; Chee et al., 2007) ; and of those reported, perifosine monotherapy has shown modest anti-tumour activity in soft tissue sarcomas and renal cell carcinomas (Bailey et al., 2006; Cho et al., 2012; Knowling et al., 2006) . Perifosine has now also been tested clinically in combination with chemotherapy and targeted therapies (see below and Table 2 , Richardson et al., 2011; Jakubowiak et al., 2012; Guidetti et al., 2014 and Gojo et al., 2013) .
Combination strategies with AKT inhibitors
Activation of the PI3K/AKT pathway has been implicated in resistance to a number of anti-cancer agents, providing a strong rationale for the clinical exploration of AKT inhibitor combinations.
Chemotherapy
AKT activation has been linked to both chemotherapy and radiation resistance. DNA-PK is one of the apical kinases involved in DNA double strand break (DSB) repair and is essential for classical non-homologous end-joining, the predominant repair pathway of DSBs in human cells (Jette & Lees-Miller, 2015) . Following the generation of DNA DSBs, AKT is activated in a DNA-PK-dependent manner and promotes survival through anti-apoptotic mechanisms that are not well described (Bozulic et al., 2008; Brown, Montaser-Kouhsari, Beck, Correspondence, & Toker, 2015; Wendel et al., 2004) . In pre-clinical studies, AKT inhibition has been shown to hypersensitise cells to a number of chemotherapeutic Chemotherapy/ radiotherapy Targeted therapy agents (Davies et al., 2012; Hirai et al., 2010; VanderWeele, Zhou, & Rudin, 2004) .
Continuous low dose perifosine has been combined safely with a number of chemotherapies (Table 2; Fu et al., 2012; Vink et al., 2006) . A randomised phase II trial of capecitabine ± perifosine as second or third line treatment for metastatic colorectal cancer showed a significant OS benefit of the combination (17.7 v 7.6 months; P = 0.0052; Bendell et al., 2011) , however these results were not validated in the phase III setting (Bendell et al., 2012) . Interestingly, the presence of a PIK3CA mutation or PTEN loss did not predict for response to the capecitabine/perifosine combination which may in part be due to the high levels of KRAS mutations in colorectal cancers (Eng et al., 2014) .
AZD5363 significantly enhances the activity of docetaxel in xenograft studies (Davies et al., 2012) . Preliminary data from a phase I trial of AZD5363 in combination with docetaxel in patients with metastatic castrate resistant prostate cancer (mCRPC) has determined a RP2D of 320 mg BID 4 days on/3 days off in combination with full dose docetaxel (75 mg/m 2 q3w) and prednisolone (5 mg BID D1-21; Crabb et al., 2016) .
DLTs were G3 rash and G3 diarrhoea. The randomised phase II trial is currently recruiting (ProCAID, NCT02121639). Early results from a phase Ib study determined a RP2D of 400 mg ipatasertib QD days 1-21 q4w in combination with weekly paclitaxel 90 mg/m 2 with grade 3
AEs of diarrhoea, fatigue and hyperglycaemia at higher doses . Promising anti-tumour activity was demonstrated in breast cancer patients with 6 PRs (22%) including 4 patients who had previously progressed on paclitaxel . Similarly, phase I/II trials of AZD5363 in combination with weekly paclitaxel are ongoing in breast and gastric cancer populations with results awaited (Table 2) . Activation of AKT has been associated with platinum resistance in pre-clinical studies of ovarian cancer (Stronach et al., 2011) . In a phase I/II study of afuresertib in combination with carboplatin (iv AUC5 q3w) and paclitaxel (iv 175 mg/m 2 q3w), the MTD of afuresertib was 150 mg daily with DLTs of G3 rash, G2 febrile neutropenia and G2 lip swelling (Blagden et al., 2016) . Promising anti-tumour activity of the combination was demonstrated and at the time of reporting, overall response rate (ORR) for platinum-resistant patients was 32.1% (95% CI: 15.9-52.4) and median progression free survival (PFS) was 7.1 months (95% CI: 6.3-9.0).
PARP inhibitors
Pre-clinical studies have demonstrated synergy between PI3K inhibition and PARP inhibition in BRCA1/2 mutant mouse models (Juvekar, Burga, & Hu, 2012) . The mechanism of this synergy has not yet been fully explained. Published data suggests that PI3K inhibition impairs DSB repair by homologous recombination through reduced expression of BRCA1 and BRCA2 (Ibrahim et al., 2012) . It is also likely however, that as with chemotherapy, the anti-apoptotic/pro-survival effects of PI3K inhibition are important in this setting. Preliminary data have shown promising anti-tumour activity of AZD5363 in combination with olaparib across a range of tumour types (Michalarea et al., 2016) . At the time of reporting, out of 37 evaluable patients, there were 10 RECIST partial or complete responses, including 3 patients with BRCA wild-type tumours and 1 patient who had previously been treated with a PARP inhibitor. The recommended phase II schedules of this combination are 300 mg BID olaparib + 400 mg BID 4/7 AZD5363 or 300 mg BID olaparib + 640 mg BID 2/7 AZD5363. Common G1-2 toxicities were nausea, fatigue, anaemia, diarrhoea, anorexia, mucositis and vomiting on both schedules.
RTK/PI3K/AKT/MTOR inhibitors
Given the multiple feedback loops within the PI3K-AKT signalling pathway, dual inhibition at different levels seems like a sensible strategy, although over-lapping toxicities limits dosing.
Pre-clinical studies have demonstrated synergy between EGFR and AKT inhibition in EGFR-wild type and mutant NSCLC cell lines (Puglisi et al., 2014 ) and a number of early phase studies of gefitinib or erlotinib in combination with MK-2206 have been completed (Table 2 ). The most common grade 3 AEs in a phase II trial of erlotinib 150 mg orally OD with MK-2206 200 mg weekly, in patients with erlotinib-resistant NSCLC, were rash, diarrhoea, fatigue and mucositis (Lara et al., 2015) . Although partial response rates were low in both EGFR wild-type and -mutant tumours (9% and 3% respectively) a disease control rate of 43% in EGFR-wild type tumours met pre-specified levels of clinical activity to warrant further investigation. A phase I trial has also shown tolerability of gefitinib in combination with MK-2206 with a RP2D of 250 mg gefitinib daily and 200 mg MK-2206 weekly with early signs of clinical activity in EGFR resistant patients with NSCLC (Lin et al., 2014) . A phase II trial exploring erlotinib in combination with MK-2206 as part of the BATTLE-2 program (NCT01248247) is ongoing.
PTEN loss and activating PIK3CA mutations have been associated with relative resistance to trastuzumab both in clinical and pre-clinical studies (Berns et al., 2007; Junttila et al., 2009; Nagata et al., 2004) . Inhibition of HER2/ErbB2 with trastuzumab has been shown to activate PTEN and attenuate PI3K/AKT signalling (Junttila et al., 2009; Nagata et al., 2004) . Trastuzumab-induced growth inhibition has also been shown to correlate with inhibition of AKT signalling in HER2+ve cells and combined inhibition of HER2 and AKT signalling is synergistic (Junttila et al., 2009) . MK-2206 has in particular, been shown to be well-tolerated in combination with trastuzumab and paclitaxel/trastuzumab in phase I trials, demonstrating promising anti-tumour activity in HER2+ and paclitaxel refractory tumours (Chien et al., 2016; Hudis et al., 2013) .
Results of a phase I trial of the mTOR inhibitor ridaforolimus in combination with MK-2206 demonstrated an MTD of 10 mg ridaforolimus OD for 5/7 and 90 mg MK-2206 weekly with 1/17 patients experiencing a DLT (G3 rash) at this dose (Gupta et al., 2015) . Other common AEs included skin rash, stomatitis, diarrhoea and anorexia. Promising antitumour activity was demonstrated in a number of heavily pre-treated breast cancer patients in an expansion cohort comprising patients with a low 'RAS pathway signature score', a 147-gene signature that has been shown to correlate with tumour dependence on RAS signalling and resistance to PI3K pathway inhibition (Loboda et al., 2010) .
MAPK pathway inhibitors
There are now several lines of evidence showing that tumours harbouring activating mutations in both the PI3K/AKT and MAPK signalling networks, require inhibition of both to negatively affect tumour growth and survival, due to significant crosstalk and redundancy between the pathways (Davies et al., 2012; She et al., 2010) . Doses of MK-2206 in combination with the MEK inhibitor selumetinib in a phase I trial of patients with solid tumours were limited predominantly by skin rash, diarrhoea and stomatitis (Tolcher, Khan, et al., 2015) . The RP2D was defined as MK-2206 135 mg weekly and selumetinib 100 mg daily, with dose reductions of both drugs required due to overlapping toxicity. Significant tumour responses were seen in patients with KRAS-mutant NSCLC and low-grade ovarian cancer, but not in KRAS-mutant colorectal cancer, again suggesting differences in biology based on tumour context. Preliminary data from a phase II trial of MK-2206 in combination with selumetinib in patients with pre-treated KRAS mutant NSCLC has shown a disease control rate of 61% (Papadimitrakopoulou et al., 2014) and the full results of this study are awaited with interest.
Preliminary results from a phase Ib study of ipatasertib in combination with the MEK inhibitor cobimetinib has shown early evidence of anti-tumour activity, but tolerability has been challenging . Afuresertib has also been tested in combination with a MEK inhibitor, trametinib with only intermittent dosing being tolerable (Tolcher, Patnaik, et al., 2015) . Continuous dosing schedules of GSK214795 in combination with trametinib have been achieved (Algazi et al., 2015; Shoushtari et al., 2016 ) and a number of trials exploring GSK2141795 in combination with trametinib are ongoing ( Table 2) . Preclinical data has clearly demonstrated that sub-maximal inhibition of the combination of MEK and AKT does not significantly increase growth inhibition of BRAF or PIK3CA mutant cells, compared to maximally inhibiting MEK or AKT alone (Stewart, Thavasu, De Bono, & Banerji, 2015) . This has significant implications for the clinical development of such combinations and requires intelligent phase I trial design that tests optimal schedules as well as doses (Lopez & Banerji, 2016) .
Hormonal treatments
The development of castrate resistant prostate cancer (CRPC) is associated with reactivation of the androgen receptor axis as well as upregulation of other pro-survival pathways including the PI3K pathway (Morgan, Koreckij, & Corey, 2009 ). The PI3K/AKT pathway is activated in 30-50% of prostate cancers, most commonly through loss of PTEN, however inhibition of this pathway alone results in up-regulation of AR signalling leading to resistance (Carver et al., 2011) . In pre-clinical studies, synergistic inhibition of AKT and androgen receptor signalling using either bicalutamide or enzalutamide results in sustained tumour growth inhibition and PSA stabilisation in mouse models of CRPC (Thomas et al., 2013; Toren et al., 2015) . Preliminary data from a phase I/II study of ipatasertib in combination with abiraterone, has shown promising clinical benefit in patients with CRPC (De Bono et al., 2016) . Patients with mCRPC, previously treated with docetaxel, were randomized 1:1:1 to three arms: ipatasertib 400 mg, ipatasertib 200 mg, or placebo, all in combination with abiraterone 1000 mg and prednisone 10 mg daily. Compared to placebo, ipatasertib 400 mg showed increased radiological PFS (median 8.2 vs 6.4 months; HR = 0.75; p = 0.17) and increased OS for ipatasertib 400 mg vs placebo (median 18.9 months vs 15.6 months; HR = 0.72; p = 0.22) (De Bono et al., 2016) . Patients with PTEN loss had a superior PFS benefit (De Bono et al., 2016) . Full results of this trial are awaited with interest. A randomised phase II trial of enzalutamide ± AZD5363 in patients with mCRPC (RE-AKT, NCT02525068) is currently recruiting. Similarly, in ER + ve breast cancer, hormone resistance is also associated with an increased dependence on PI3K/AKT signalling (Miller et al., 2010) and treatment of breast cancer cell lines and xenografts with AZD5363 in combination with fulvestrant is superior to AZD5363 alone (Fox, Kuba, Miller, Davies, & Arteaga, 2013; Ribas et al., 2015) . FAKTION (NCT01992952), a randomised phase II trial of fulvestrant ± AZD5363 is ongoing.
Future directions and conclusions
AKT remains a central player in the PI3K-AKT signalling network and promising data from a number of phase II combination trials look set to pave the way for phase III studies and hopefully, clinical registration of some these compounds. Patient selection remains key, with AKT1 E17K looking like a particularly strong biomarker predictive of response to AZD5363 monotherapy. A basket trial approach to clinical trial design is becoming increasingly popular and suits collections of low frequency, but high potency mutations such as AKT1 E17K . Although potentially slow to complete, the clinical impact for patients harbouring such mutations should not deter licensing of compounds for such niche tumour populations. The presence of AKT1 E17K and other genetic aberrations (such as activating PIK3CA mutations and PTEN loss) needs to be put in molecular context however as co-activation of other pro-survival pathways is likely to require combination treatment strategies as demonstrated with AKT and MEK inhibition. Other potential biomarkers such as the RAS pathway signature score and proteomic signatures predictive of response to AKT inhibitors attempt to look beyond the PI3K/AKT pathway itself and should be explored further (Cheraghchi-Bashi et al., 2015; Loboda et al., 2010) . Interestingly, intermittent high doses of AKT inhibitors have been shown to be a more effective strategy both clinically and pre-clinically. High doses appear to be required for induction of apoptosis and intermittent schedules overcome the low therapeutic index of these compounds. This is particularly important in combination studies where toxicity is often limiting (Shimizu et al., 2012) . Current preclinical data suggests intermittent dosing that inhibits AKT signalling to a greater extent is more efficacious than chronically inhibiting AKT to a lesser degree as a clinical strategy (Lopez & Banerji, 2016; Stewart et al., 2015) . Interestingly due to feedback inhibition within the PI3K/AKT pathway, intermittent dosing may also delay treatment resistance. Despite the challenges, there remains intense enthusiasm in establishing AKT inhibitors within the future collection of personalised treatments for cancer and numerous clinical trials of AKT inhibitor combinations are actively recruiting.
The potential applications of AKT inhibitors are numerous. The scientific community has multiple drugs in the clinic with exciting potential to influence treatment paradigms in multiple cancers. Carefully thought out clinical trials with tolerable clinical schedules, appropriate combinations and patient selection biomarkers will be needed to maximally exploit the full potential of this class of agents.
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